基本説明
New in paperback. Hardcover was published in 2006. Physician-historian Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical markeing. Highlits the complex historical role of pharmaceuticals in the transformation of disease categories.
Full Description
Greene provides suggestions on how to address some of the problems inherent in medical prevention.
Contents
Preface
Acknowledgments
Introduction: The Pharmacopoeia of Risk Reduction
Part One: Diuril and Hypertension, 1957-1977
1. Releasing the Flood Waters: The Development and Promotion of Diuril
2. Shrinking the Symptom, Growing the Disease: Hypertension after Diuril
Part Two: Orinase and Diabetes, 1960-1980
3. Finding the Hidden Diabetic: Orinase Creates a New Market
4. Risk and the Symptom: The Trials of Orinase
Part Three: Mevacor and Cholesterol, 1970-2000
5. The Fall and Rise of a Risk Factor: Cholesterol and Its Remedies
6. Know Your Number: Cholesterol and the Threshold of Pathology
Conclusion: The Therapeutic Transition
Notes
Index
